These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 12713985)

  • 1. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.
    Wilder JL; Pavlik E; Straughn JM; Kirby T; Higgins RV; DePriest PD; Ueland FR; Kryscio RJ; Whitley RJ; Nagell Jv
    Gynecol Oncol; 2003 May; 89(2):233-5. PubMed ID: 12713985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
    Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
    Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range.
    Santillan A; Garg R; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK; Bristow RE
    J Clin Oncol; 2005 Dec; 23(36):9338-43. PubMed ID: 16361633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
    Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
    Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
    Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
    Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
    Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
    Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
    Zaucha R; Kobierska A
    Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
    Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
    Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
    Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
    J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
    Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
    J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
    Low RN; Duggan B; Barone RM; Saleh F; Song SY
    Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination--a longitudinal study.
    Low RN; Saleh F; Song SY; Shiftan TA; Barone RM; Lacey CG; Goldfarb PM
    Radiology; 1999 May; 211(2):519-28. PubMed ID: 10228537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
    Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
    Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum CA-125 assay, and conventional radiological modalities.
    Antunovic L; Cimitan M; Borsatti E; Baresic T; Sorio R; Giorda G; Steffan A; Balestreri L; Tatta R; Pepe G; Rubello D; Cecchin D; Canzonieri V
    Clin Nucl Med; 2012 Aug; 37(8):e184-8. PubMed ID: 22785525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation".
    Menczer J
    Gynecol Oncol; 2005 Mar; 96(3):906-7; author reply 907. PubMed ID: 15721450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.